{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4-Part+Intervention&page=26",
    "query": {
      "intervention": "4-Part Intervention",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 745,
    "total_pages": 75,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4-Part+Intervention&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4-Part+Intervention&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T18:55:48.017Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01999738",
      "title": "Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "EC1456 and EC20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endocyte",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2013-10",
      "completion_date": "2018-04-26",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999738"
    },
    {
      "nct_id": "NCT01781806",
      "title": "A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "emtricitabine 200mg/tenofovir 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 328,
      "start_date": "2013-05",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781806"
    },
    {
      "nct_id": "NCT05508009",
      "title": "Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SIOD",
        "Cystinosis",
        "FSGS",
        "SLE Nephritis",
        "CKD Stage 4"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide 1200 mg/Kg",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 100 mg/Kg",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System",
          "type": "DEVICE"
        },
        {
          "name": "Kidney Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Alice Bertaina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-01-10",
      "completion_date": "2034-10",
      "has_results": false,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05508009"
    },
    {
      "nct_id": "NCT05642364",
      "title": "Virtual Reality in Hemodialysis to Improve Psychological Well-being",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "End Stage Kidney Disease",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "Joviality(TM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Inert Virtual Reality",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Illinois at Urbana-Champaign",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2023-06-22",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05642364"
    },
    {
      "nct_id": "NCT03625999",
      "title": "A Novel Intervention for Training Auditory Attention in Adolescents With Autism Spectrum Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Autism"
      ],
      "interventions": [
        {
          "name": "video game training exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University Charles River Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "13 Years to 20 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-08-01",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-04-09",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03625999"
    },
    {
      "nct_id": "NCT04132557",
      "title": "A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Lisdexamfetamine",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Amphetamine",
          "type": "DRUG"
        },
        {
          "name": "Dextroamphetamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 430000,
      "start_date": "2019-10-09",
      "completion_date": "2019-10-25",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04132557"
    },
    {
      "nct_id": "NCT04898907",
      "title": "Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "ANG-3777 (Therapeutic Dose)",
          "type": "DRUG"
        },
        {
          "name": "ANG-3777 (Supra-therapeutic Dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angion Biomedica Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2021-06",
      "completion_date": "2021-09",
      "has_results": false,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04898907"
    },
    {
      "nct_id": "NCT02509507",
      "title": "Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Liver Metastases",
        "Cutaneous or Subcutaneous Lymph Node",
        "Liver Tumors"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2016-02-05",
      "completion_date": "2023-07-11",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02509507"
    },
    {
      "nct_id": "NCT03152058",
      "title": "IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Risk Pregnancy",
        "Pregnancy Complications",
        "Antiphospholipid Syndrome in Pregnancy",
        "Lupus Anticoagulant Disorder"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Ware Branch",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 55,
      "start_date": "2017-05-17",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 2,
      "location_summary": "New York, New York • Salt Lake City, Utah",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152058"
    },
    {
      "nct_id": "NCT00821652",
      "title": "Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod",
          "type": "DRUG"
        },
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-11-04T18:55:48.017Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821652"
    }
  ]
}